- Home
- EWTX vs JPC Comparison
EWTX vs JPC Comparison
Compare EWTX & JPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- JPC
- Stock Information
- Founded
- EWTX 2017
- JPC 2003
- Country
- EWTX United States
- JPC United States
- Employees
- EWTX N/A
- JPC N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- JPC Investment Managers
- Sector
- EWTX Health Care
- JPC Finance
- Exchange
- EWTX Nasdaq
- JPC Nasdaq
- Market Cap
- EWTX 2.3B
- JPC N/A
- IPO Year
- EWTX 2021
- JPC N/A
- Fundamental
- Price
- EWTX $20.13
- JPC $7.92
- Analyst Decision
- EWTX Buy
- JPC
- Analyst Count
- EWTX 8
- JPC 0
- Target Price
- EWTX $45.38
- JPC N/A
- AVG Volume (30 Days)
- EWTX 1.5M
- JPC 998.5K
- Earning Date
- EWTX 03-03-2025
- JPC 01-01-0001
- Dividend Yield
- EWTX N/A
- JPC 7.57%
- EPS Growth
- EWTX N/A
- JPC N/A
- EPS
- EWTX N/A
- JPC N/A
- Revenue
- EWTX N/A
- JPC N/A
- Revenue This Year
- EWTX N/A
- JPC N/A
- Revenue Next Year
- EWTX N/A
- JPC N/A
- P/E Ratio
- EWTX N/A
- JPC N/A
- Revenue Growth
- EWTX N/A
- JPC N/A
- 52 Week Low
- EWTX $14.90
- JPC $5.94
- 52 Week High
- EWTX $38.12
- JPC $7.36
- Technical
- Relative Strength Index (RSI)
- EWTX 28.86
- JPC 43.31
- Support Level
- EWTX $21.58
- JPC $7.87
- Resistance Level
- EWTX $25.36
- JPC $7.99
- Average True Range (ATR)
- EWTX 1.99
- JPC 0.05
- MACD
- EWTX -0.38
- JPC -0.00
- Stochastic Oscillator
- EWTX 2.67
- JPC 31.25
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.